Company L&C Bio Co., Ltd

Equities

A290650

KR7290650001

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Quarterly revenue - Rate of surprise

Sector Medical Devices & Implants

End-of-day quote Korea S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
21,050 ^KRW	+0.96%		-0.24%	-27.41%

03-27	Ray Co., Ltd. announced that it has received KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.	CI
03-25	Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.	CI

L&C BIO Co., Ltd is a Korea-based Company mainly engaged in the regenerative medicine business. The Company mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The Company also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.

Number of employees: 121

KRW in Million	2022	Weight	2023	Weight	Delta
Human Tissue Products 78.1 %	40,658	77.3 %	53,764	78.1 %	+32.23%
Service 14.6 %	9,244	17.6 %	10,023	14.6 %	+8.43%
Human Tissue Merchandise 7.4 %	2,671	5.1 %	5,083	7.4 %	+90.32%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 94.3 %	48,673	92.6 %	64,934	94.3 %	+33.41%
Overseas 5.7 %	3,900	7.4 %	3,936	5.7 %	+0.93%

Managers	Title	Age	Since
Hwan-Chul Lee CEO	Chief Executive Officer	48	-
Hyung-Gu Kim BRD	Director/Board Member	57	-
Jong-Oh Choi AUD	Comptroller/Controller/Auditor	52	-

Members of the board	Title	Age	Since
Hwan-Chul Lee CEO	Chief Executive Officer	48	-
Hyung-Gu Kim BRD	Director/Board Member	57	-
Hae-Seok Hwang BRD	Director/Board Member	68	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	22,684,891	15,493,977 ( 68.30 %)	0	68.30 %

Name	Equities	%	Valuation
Hwan-Chul Lee 27.88 %	6,325,490	27.88 %	109 M ₩
VIP Research & Management Inc. 6.621 %	1,501,879	6.621 %	26 M ₩
Hyun-jung Hwang 1.318 %	299,028	1.318 %	5 M ₩
Global Medical Research Center 1.038 %	235,410	1.038 %	4 M ₩
Hyung-Gu Kim 0.9673 %	219,426	0.9673 %	4 M ₩
Ki-min Kim 0.3032 %	68,790	0.3032 %	1 M ₩
Kwang-in Lee 0.2815 %	63,851	0.2815 %	1 M ₩
Il-sun Hwang 0.2124 %	48,180	0.2124 %	833 868 ₩
Hwan Kim Sung 0.1872 %	42,465	0.1872 %	734 956 ₩
Mi-sun Lee 0.1587 %	36,000	0.1587 %	623 064 ₩

Name	Equities	%	Valuation
CUREXO INC. 3.55%	1,458,221	3.55%	14,676,994 $

L&C BIO Co., Ltd.

Unit605-607, Suntech Building 474, Dunchon-daero

13229, Seongnam

http://www.lncbio.co.kr

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Medical Devices & Implants

	1st Jan change	Capi.
L&C BIO CO., LTD	-27.41%	349M
STRYKER CORPORATION	+10.39%	126B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+2.52%	8.97B
GLAUKOS CORPORATION	+38.96%	5.56B
INSPIRE MEDICAL SYSTEMS, INC.	-17.50%	4.99B
AXONICS, INC.	+8.36%	3.44B
ENOVIS CORPORATION	-8.84%	2.8B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-7.52%	2.18B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-3.00%	2.16B
DOUBLE MEDICAL TECHNOLOGY INC.	-21.88%	1.82B

Medical Devices & Implants